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http://dx.doi.org/10Failure to maintain a normal in vivo erythrocyte half-life results in the development of hemo-
lytic anemia. Half-life is affected by numerous factors, including energy balance, electrolyte
gradients, reactive oxygen species, and membrane plasticity. The heterotrimeric AMP-
activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase
that acts as a critical regulator of cellular energy balance. Previous roles for the alpha 1
and gamma 1 subunits in the control of erythrocyte survival have been reported. In the
work described here, we studied the role of the beta 1 subunit in erythrocytes and observed
microcytic anemia with compensatory extramedullary hematopoiesis together with spleno-
megaly and increased osmotic resistance. Copyright  2016 ISEH - International Society
for Experimental Hematology. Published by Elsevier Inc. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).Erythrocytes are enucleated, terminally differentiated
cells with a finite life span and an estimated turnover of
1% every day. To deal with stress, hemolysis, and/or hyp-
oxia, the production of erythrocytes can be substantially
modulated. In vivo control of erythrocyte survival is
affected by many factors, including energy balance, main-
tenance of electrolyte gradients, and control of reactive
oxygen species. Alterations to erythrocyte membrane
deformability have a major role in regulating cellular
function and intravascular survival, with reduced deform-
ability resulting in splenic sequestration of abnormal cells,
shortened half-life, and the clinical presentation of hemo-
lytic anemia [1].
The evolutionary conserved serine/threonine kinase
AMP-activated protein kinase (AMPK) is a critical regu-
lator of energy balance [2,3]. AMPK is a heterotrimericibuted equally to this study.
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4@sanger.ac.uk
related to this article can be found online at http://
exphem.2016.09.006.
 2016 ISEH - International Society for Experimental Hem
//creativecommons.org/licenses/by/4.0/).
.1016/j.exphem.2016.09.006complex containing a catalytic alpha subunit paired with
beta and gamma regulatory subunits. There are several iso-
forms for each subunit encoded by separate genes, two
alpha (Prkaa1 and Prkaa2), two beta (Prkab1 and Prkab2),
and three gamma (Prkag1, Prkag2, and Prkag3). Prkaa1
and Prkag1 can control oxidative stress, erythrocyte-
intrinsic cellular metabolic stress, and membrane elasticity,
making them critical regulators of erythrocyte integrity and
life span [4–7]. However, the specific role of beta subunit
isoforms in the context of erythrocyte development has
not been studied.
Here we report that Prkab1-deficient mice present with
splenomegaly, increased splenic iron deposits, microcytic
anemia, compensatory extramedullary hematopoiesis,
altered erythrocyte morphology, and increased erythrocyte
osmotic resistance.Methods
Mice
Generation of Prkab1tm1b(KOMP)Wtsi (hereafter referred to as
Prkab1tm1b) mice was performed using ES cell clone
EPD0033_3_C09. Genotyping was carried out according to Ryder
et al. [8] with cre conversion as reported [9]. All experiments wereatology. Published by Elsevier Inc. This is an open access article under the
65E.L. Cambridge et al./ Experimental Hematology 2017;45:64–68performed in accordance with the UK Home Office regulations
and UK Animals (Scientific Procedures) Act 1986 and approved
by the Wellcome Trust Sanger Institute animal welfare and ethical
review body.
Gene expression analysis
RNA was extracted from spleens using Purelink RNA mini kit
(Ambion). Gene expression was assessed using FAM-conjugated
TaqMan assays as listed in the Supplementary Methods (online
only, available at www.exphem.org). Template RNA was added
in duplex reactions in triplicate using B2m VIC primer limited
probe (Mm00437762_m1) as the endogenous control using the
EXPRESS One-Step Superscript qRT-PCR Kit (Thermo Scienti-
fic) and an Applied Biosystems 7900HT analyzer. Relative gene
expression between endogenous control and target gene was
analyzed using the DDCT method [10] with RQ manager (Life
Technologies) applying automatic thresholds.
Western blot analysis
Protein lysates were prepared from spleens, with protein quantifi-
cation, electrophoresis, transfer, and antibody incubations per-
formed according to standard protocols. Blots were visualized
using horseradish peroxidase-conjugated secondary antibodies
and ECL reagents, then imaged with a LAS 4000 (GE Healthcare).
The primary antibodies used were AMPK beta 1 (1/1,000, No.
12063), AMPK beta 2 (1/1,000, No. 4148), AMPK pan alpha
(all Cell Signalling Technology, 1/1,000, F6 No. 2793), and vincu-
lin (Sigma, 1/5000, V284).
Blood collection and analysis
Retro-orbital or tail vein blood was collected into EDTA-coated
tubes for hematology or heparinized tubes for plasma preparation.
Complete blood counts were determined using a Scil Vetabc sys-
tem. Plasma was analyzed for bilirubin, iron, and ferritin using an
Olympus AU400 analyzer (Beckman Coulter) with reagents sup-
plied by Beckman Coulter or Randox. Erythropoietin was deter-
mined using a Meso Scale Discovery array.
Histologic analysis
Spleen, liver, and leg bones were fixed in formalin and embedded
in paraffin, and sections were stained with hematoxylin and eosin
or Perls’ Prussian blue according to standard methods. These were
assessed in a blinded manner for any pathologic abnormalities.
Scanning electron microscopy (SEM) was performed as previ-
ously described [11] with erythrocytes adhered to poly-L-lysine-
coated coverslips.
Erythropoiesis analysis
Staining of single-cell suspensions of spleen, bone marrow, and
whole blood with CD71, Ter119, CD45, Syto 16, and Sytox
blue was performed as previously described [12] and analyzed
on a BD LSRII instrument (full details in Supplementary
Methods).
In vivo clearance of erythrocytes
This was performed as described previously [4] with the exception
that samples were labeled with either 10 mmol/L Vybrant CFDA
(Prkab1þ/þ) or 1 mmol/L CellTracker Deep red (Prkab1tm1b/tm1b,
both Molecular Probes). Erythrocytes were counted and adjusted
to 2  106 RBC/mL, and the two genotypes were pooled and in-
jected via the tail vein into recipient mice (10 weeks old) to trans-fuse 2  108 RBCs/genotype (full details in Supplementary
Methods).
Osmotic resistance assay
This was performed essentially as described [4] with hematocrit
adjusted to 0.8% with 0.9% saline solution.
Statistical analysis
All data was analyzed in Prism Version 6 (Graph Pad) and
analyzed with an unpaired two-tailed Student t test, Mann–Whit-
ney test or two-way analysis of variance as indicated in the figure
legends.Results
Prkab1tm1b/tm1b mice exhibited greatly reduced expression
of Prkab1 that was accompanied by a significant (possibly
compensatory) increase in Prkaa1 and Prkag1
(Supplementary Figure E1A, online only, available at
www.exphem.org). This was confirmed by immunoblot
analysis, which supports observations from Prkag1
knockout mice [4] and another Prkab1 knockout mouse
line [13] that genetic deletion of one part of the AMPK het-
erotrimeric complex results in protein dysregulation of
other parts of the complex, as there was no detectable alpha
protein (pan-AMPK alpha antibody) in Prkab1tm1b/tm1b
spleen lysates (Supplementary Figure E1B).
At 16 weeks of age, Prkab1tm1b/tm1b mice had signifi-
cantly reduced hemoglobin (Fig. 1A) and hematocrit
(Fig. 1B). Reductions in erythrocyte number (Fig. 1C)
and mean corpuscular hemoglobin concentration
(Fig. 1D) were observed only in a sex-specific manner;
however, erythrocytes in Prkab1tm1b/tm1b mice were signif-
icantly smaller (Fig. 1E), with an increased red blood cell
distribution width (Fig. 1F) in both sexes. These altered
erythrocyte indices indicate a microcytic anemia with ani-
socytosis, similar to that reported in mice deficient in
Prkaa1 or Prkag1 [4–7]. The leukocyte lineage was unaf-
fected by deletion of Prkab1 (Supplementary
Figure E1C), and there were no differences in the circu-
lating platelet count (Supplementary Figure E1D). Howev-
er, there was an increase in the size of the platelets in both
sexes (Supplementary Figure E1E). At 4 and 6 weeks of
age, the anemia was normocytic (Supplementary
Figure E2A–G, online only, available at www.exphem.
org; data not shown).
Scanning electron microscopy confirmed anisocytosis;
erythrocytes from Prkab1tm1b/tm1b mice varied in appear-
ance, with features of acanthocytes, schistocytes, stomato-
cytes, and echinocytes (Fig. 1G). We then determined
osmotic resistance; Prkab1-deficient erythrocytes had a
left-shifted curve indicative of increased osmotic resistance
(Fig. 1H), in agreement with the previously observed find-
ings in Prkaa1-and Prkag1-deficient mice [4–7].
At necropsy, Prkab1tm1b/tm1b mice presented with
splenomegaly (Fig. 2A and B), although not to the same de-
gree as Prkag1/ and Prkaa1/ mice [4–7]. We
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Figure 1. Prkab1-deficient mice present with anemia, erythrocyte morphologic abnormalities, and increased erythrocyte osmotic resistance. (A) Hemoglo-
bin, (B) hematocrit, (C) red blood cell count, (D) mean corpuscular hemoglobin concentration, (E) mean corpuscular volume, and (F) red blood cell distri-
bution width of 16-week-old Prkab1þ/þ and Prkab1tm1b/tm1b mice. **p! 0.01, and ****p! 0.0001, unpaired two-tailed Student t test. (G) Representative
SEM images of erythrocytes from Prkab1þ/þ and Prkab1tm1b/tm1b mice. (H) Osmotic resistance of Prkab1þ/þ and Prkab1tm1b/tm1b erythrocytes (combined
males and females). ****p! 0.0001 as determined by a repeated-measures two-way analysis of variance with Sidak’s multiple comparison test adjusting for
multiple testing, the insert is % of NaCl for 50% hemolysis of erythrocytes ****p! 0.0001, unpaired two-tailed Student t test. All data are representative of
three independent experiments or two mice for SEM analysis. Each symbol represents an individual mouse with the line at the mean except for (H), where
n 5 10 for Prkab1þ/þ and n 5 9 for Prkab1tm1b/tm1b with mean 6 standard error of the mean.
66 E.L. Cambridge et al./ Experimental Hematology 2017;45:64–68determined the level of total bilirubin in the plasma, an in-
dicator of erythrocyte destruction, and although increased
in Prkab1tm1b/tm1b mice, this did not reach significance in
any of the cohorts tested (Fig. 2C). Prkab1tm1b/tm1b spleens
exhibited an expansion of the peripheral red pulp caused by
increased extramedullary hematopoiesis and increased red
cell breakdown with hemosiderin in the red pulp
(Fig. 2D). Hemolytic anemia often results in changes in tis-
sue iron deposits, and we found a significant increase insplenic iron deposits in Prkab1tm1b/tm1b mice (Fig. 2E),
with a concomitant increase in circulating levels of ferritin
(Supplementary Figure E3A, online only, available at www.
exphem.org) and decrease in iron concentration
(Supplementary Figure E3B). Circulating erythropoietin
was significantly increased in Prkab1tm1b/tm1b mice
(Fig. 2F), as was the percentage of reticulocytes (Fig. 2G).
There was an increase in the ratio of Ter119þ to CD45þ
cells in the spleen (Fig. 2H), as well as increase, in
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Figure 2. Prkab1-deficient mice have splenomegaly, extramedullary hematopoiesis, and splenic iron deposits. (A) Spleen weight. (B) Spleen/body weight
ratio (mg/g). (C) Plasma bilirubin concentration. (D) Hematoxylin and eosin-stained sections of spleen (100 magnification). (E) Perls’-stained sections of
spleen (100 magnification). (F) Plasma erythropoietin. (G) Percentage of circulating reticulocytes. (H) Splenic erythroid (Ter119)/leukocyte (CD45) ratio.
(I) Percentage of splenic erythroblasts. (J) Percentages of splenic reticulocytes and erythrocytes. For all, *p ! 0.05, **p ! 0.01, ***p ! 0.001, and
****p! 0.0001, unpaired two-tailed Student t test except for spleen/body weight ratio and Ter119/CD45 ratio, which were analyzed with a Mann–Whitney
test. All data are representative of three independent experiments or four mice for histology analysis; each symbol represents an individual mouse with the
line at the mean.
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68 E.L. Cambridge et al./ Experimental Hematology 2017;45:64–68percentages of erythroblasts (Fig. 2I) and reticulocytes,
with a concomitant decrease in mature erythrocytes
(Fig. 2J). The bone marrow exhibited a reduction in adipo-
cytes of the marrow stroma and a mild hematopoietic hy-
perplasia with a mild increase in erythroid subsets
(Supplementary Figure E3C–E). These observations would
suggest a reactive increase in erythroid hematopoiesis in
both bone marrow and spleen in response to the observed
hemolytic anemia. A similar hemolytic anemia with
compensatory extramedullary hematopoiesis has been
observed in Prkaa1-and Prkag1-deficient mice [4–7].
Previous studies on Prkag1/ and Prkaa1/ mice
have found that deficiency in either gene results in a
decreased half-life in vivo [4,5,7]. Via adoptive transfer
of fluorescence- labeled erythrocytes, we observed no dif-
ference in the half-life of Prkab1tm1b/tm1b erythrocytes
when transferred into wild-type mice, compared with the
co-transferred wild-type erythrocytes (Supplementary
Figure E3F), or when transferred into Prkab1tm1b/tm1b
mice (Supplementary Figure E3G). However, we cannot
rule out the possibility that the method employed skews
the analysis if the ex vivo fluorescence labeling preferen-
tially occurs in ‘‘normal’’ erythrocytes given the heteroge-
neous morphologic alterations to the erythrocytes in
Prkab1tm1b/tm1b mice.
Discussion
In summary we report a key role for the AMPK beta 1 sub-
unit in erythrocyte development similar to that observed for
alpha 1 and gamma 1 subunits. Deletion of Prkab1 resulted
in regenerative hemolytic anemia, splenomegaly, and
splenic iron deposition with enhanced erythropoiesis in
the spleen and, to a lesser extent, bone marrow. Erythro-
cytes from deficient mice presented with multiple morpho-
logic alterations and increased osmotic resistance.
Acknowledgments
The authors thank Yvette Hooks, Wellcome Trust Sanger Institute,
for histology technical support and Professor Elspeth Milne and
Dr. Paola Cazzini, Royal (Dick) School for Veterinary Studies,
University of Edinburgh, for expert opinions on murine red blood
cell morphology.This work was funded by the Wellcome Trust (Grant
WT098051).
Author contributions
ELC, ZM, SC, MJA, DAG, CI, SC, CBR, AS, LK, KH, The
Sanger Mouse Genetics Project, and AOS generated the
data. ELC, ZM, MJA, DAG, CI, and AOS analyzed the
data. The Sanger Mouse Genetics Project generated, geno-
typed, and phenotyped the mice, DJA, JKW, and AOS led
the project. AOS wrote the article with contributions from
all authors.
References
1. Mohandas N, Gallagher PG. Red cell membrane: Past, present, and
future. Blood. 2008;112:3939–3948.
2. Carling D, Thornton C, Woods A, Sanders MJ. AMP-activated protein
kinase: New regulation, new roles? Biochem J. 2012;445:11–27.
3. Hardie DG. AMP-activated/SNF1 protein kinases: Conserved guard-
ians of cellular energy. Nat Rev Mol Cell Biol. 2007;8:774–785.
4. Foretz M, Hebrard S, Guihard S, et al. The AMPK gamma1 subunit
plays an essential role in erythrocyte membrane elasticity, and its ge-
netic inactivation induces splenomegaly and anemia. FASEB J. 2011;
25:337–347.
5. Wang S, Dale GL, Song P, Viollet B, Zou MH. AMPKalpha1 deletion
shortens erythrocyte life span in mice: Role of oxidative stress. J Biol
Chem. 2010;285:19976–19985.
6. Foretz M, Guihard S, Leclerc J, et al. Maintenance of red blood cell
integrity by AMP-activated protein kinase alpha1 catalytic subunit.
FEBS Lett. 2010;584:3667–3671.
7. Foller M, Sopjani M, Koka S, et al. Regulation of erythrocyte survival
by AMP-activated protein kinase. FASEB J. 2009;23:1072–1080.
8. Ryder E, Gleeson D, Sethi D, et al. Molecular characterization of
mutant mouse strains generated from the EUCOMM/KOMP-CSD
ES cell resource. Mamm Genome. 2013;24:286–294.
9. Ryder E, Doe B, Gleeson D, et al. Rapid conversion of
EUCOMM/KOMP-CSD alleles in mouse embryos using a cell-
permeable Cre recombinase. Transgenic Res. 2014;23:177–185.
10. Pfaffl MW. A new mathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
11. Yu J, Rossi R, Hale C, Goulding D, Dougan G. Interaction of enteric
bacterial pathogens with murine embryonic stem cells. Infect Immun.
2009;77:585–597.
12. Boles NC, Peddibhotla S, Chen AJ, Goodell MA, Rosen JM. Chk1
haploinsufficiency results in anemia and defective erythropoiesis.
PLoS One. 2010;5:e8581.
13. Dzamko N, van Denderen BJ, Hevener AL, et al. AMPK beta1 dele-
tion reduces appetite, preventing obesity and hepatic insulin resis-
tance. J Biol Chem. 2010;285:115–122.
Supplementary methods
Gene expression analysis
The FAM conjugated TaqMan Gene Expression Assays
used were as follows: Prkaa1 (Mm01296700_m1), Prkaa2
(Mm01264789_m1), Prkab1 (Mm01201921_m1), Prkab2
(Mm01257133_m1), Prkag1 (Mm00450298_g1), Prkag2
(Mm00513977_m1), Prkag3 (Mm00463997_m1).
Western blot analysis
Spleen samples were homogenized in IP lysis buffer
(Thermo Fisher) supplemented with protease and phospha-
tase inhibitors (cOmplete and PhosSTOP both Roche) using
M tubes and an OctoMACS (Miltenyi Biotec) with program
protein_01. Samples were left on ice for 15 min and then
cleared by centrifugation for 10 min at 20,000g at 4C.
The protein concentration of the supernatant was deter-
mined using the BCA kit from Pierce according to the man-
ufacturer’s instructions. Protein samples (15 mg/lane) were
prepared for electrophoresis on 4–12% 1.0 mm NuPage
Bis–Tris gels with 4 LDS buffer and 10 sample
reducing agent (all from Invitrogen). Novex sharp pre-
stained molecular weight ladders were also applied to the
gel, and MOPS running buffer (Invitrogen) was used for
protein separation. Proteins were transferred to PVDF
membrane using wet transfer in the XCell II blot module.
Once transferred, membranes were blocked with 5% nonfat
milk powder in Tris-buffered saline with 0.1% Tween 20
(TBS-T) for 1 hour with rocking at room temperature. Blots
were then cut to allow them to be separately probed with
primary antibodies using the molecular weight markers as
a guide. Primary antibodies were all prepared in 2.5%
nonfat milk in TBS-T and incubated overnight at 4C
with rocking. Blots were washed before incubation in
horseradish peroxidase-conjugated secondary antibodies
for 90 min at room temperature (anti-rabbit or anti-mouse
HRP [Abcam] 1/5,000 dilution in 2.5% nonfat milk in
TBS-T). After being washed, blots were visualized using
an enhanced chemiluminescence spray (Advansta, National
Diagnostics) and imaged in an LAS 4000 (GE Healthcare,
Chalfont). Primary antibodies were used against AMPK
beta 1 (Cell Signalling Technology, 1/1000, No. 12063),
AMPK beta 2 (Cell Signalling Technology, 1/1,000, No.
4148), and AMPK pan alpha (Cell Signalling Technology,
1/1,000, F6 No. 2793), and vinculin (Sigma, 1/5000,
V284) acted as a loading control.
Erythropoiesis analysis
Single-cell suspensions were prepared from spleen and
bone marrow using D-PBS according to standard methods.
Cells from spleen and bone marrow plus blood were stained
for 30 min at 4C with Ter119-APC (0.33 mg/mL, TER-
119, Biolegend), CD71-PE-Cy7 (0.1 mg/mL, RI7217,
Biolegend), and CD45-Alexa Fluor 700 (0.833 mg/mL,
30-F11, Biolegend) antibodies after blocking with 1 mg
Mouse FC block (2.4G2, BD Biosciences) for 10 min. After
being washed, the samples were incubated in 0.5 mmol/L
Syto 16 and 1 mmol/L Sytox Blue (both Invitrogen) for
15 min at room temperature, prepared in FACS buffer (Dul-
becco’s phosphate-buffered saline without calcium or mag-
nesium [D-PBS, Gibco], supplemented with 1% bovine
serum albumin [Sigma]). Samples were washed prior to
acquisition on a BD LSRII instrument. Dead cells were
excluded (Sytox Bluehigh) and singlets by FSC-A versus
FSC-H and SSC-H versus SSC-W. Erythroid cells were
identified as Ter119þ and leukocytes as CD45þ, with eryth-
roblasts CD71þ Syto 16high, reticulocytes CD71high Syto
16low, and mature erythrocytes as CD71– Syto 16neg.
In vivo clearance of erythrocytes
Blood (700 mL) was collected under terminal anesthesia
from the retro-orbital sinus into EDTA-coated tubes and
was washed twice with 14 mL of D-PBS to remove all
serum proteins that would quench the fluorescence label-
ing. Blood from two mice of the same genotype were
pooled and labeled with either 10 mmol/L Vybrant CFDA
(wild type) or 1 mmol/L CellTracker Deep Red (mutants)
for 30 min at 37C with constant gentle mixing by rota-
tion. The reaction was quenched by the addition of 10
vol of D-PBS containing 5% fetal bovine serum (Sigma).
Erythrocytes were pelleted and washed twice with D-
PBS prior to counting using a Scil Vetabc system. Erythro-
cyte concentrations of each genotype sample were adjusted
with D-PBS to 2  106 RBC/mL. The two genotypes were
then pooled, and 200 mL was injected into C57BL/6N
recipient mice (10 weeks old) to transfuse 2  108
RBCs/genotype. Blood samples (2 mL) were collected at
the indicated time points and placed in 3 mL of flow cy-
tometry buffer (D-PBS with 2 mmol/L EDTA and 0.5%).
The samples were mixed and acquired on a BD LSRII in-
strument with CFDA detected in the FITC channel (excita-
tion: 488 nm, emission: 530/30) and CellTracker Deep Red
in the APC channel (excitation: 633, emission: 660/20).
Gates were set around the CFDA or CellTracker Deep
Red single positive erythrocytes, and the percentage of to-
tal erythrocytes was determined. A total of 5,000 labeled
erythrocytes were acquired, and application settings in
BD FACSDiva software were used to standardize the in-
strument voltage settings over the experiment duration.
The percentage of fluorescent erythrocytes was calculated
as the percentage of the total labeled fraction determined
from the blood collected 60 min after injection.
Osmotic resistance assay
Blood was collected as described above, and hematocrit
levels were determined using a Vetabc analyzer. The he-
matocrit of the samples was adjusted to 0.8% with 0.9%
saline solution. This 0.8% hematocrit solution was added
to 12 wells of a 96-well V-bottom plate (per mouse), and
the erythrocytes were pelleted (400g, 3 min). The
68.e1E.L. Cambridge et al./ Experimental Hematology 2017;45:64–68
supernatant was discarded, and the erythrocytes were re-
suspended in 200 mL of saline solutions or water as indi-
cated in the figure. The samples were left for 1 hour at
room temperature, and erythrocytes were pelleted. The
supernatant (75 mL) was transferred to a flat-bottom plate,
and the absorbance at 405 nm was measured. The percent-
age hemolysis was determined by normalizing the reading
of erythrocytes in water to the saline solutions.
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AC
B
D E
Supplementary Figure E1. Molecular and phenotypic characterization of Prkab1-deficient mice. (A) Mean gene expression of AMPK subunits in
Prkab1þ/þ and Prkab1tm1b/tm1b spleen RNA. n 5 5 per genotype, with error bars representing standard errors of the mean. (B) Immunoblot analysis of
AMPK subunits in Prkab1þ/þ and Prkab1tm1b/tm1b spleen protein lysates. *IgG heavy chain. (C) White blood cell count. (D) Mean platelet volume. (E)
Platelet count of 16-week-old Prkab1þ/þ and Prkab1tm1b/tm1b mice. *p ! 0.05, **p ! 0.01, *** p ! 0.001, and ****p ! 0.0001. Student’s t test, hema-
tology data are representative of three independent experiments. Each symbol represents an individual mouse with the line at the mean.
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Supplementary Figure E2. Prkab1tm1b/tm1b mice have altered hematologic parameters at 4 weeks of age. (A) Hemoglobin, (B) hematocrit, (C) red blood
cell count, (D) mean corpuscular hemoglobin concentration, (E) red blood cell distribution width, (F) mean corpuscular volume, and (G) mean platelet vol-
ume of 4-week-old Prkab1þ/þ and Prkab1tm1b/tm1b mice. *p! 0.05, ***p! 0.001, and ****p! 0.0001, unpaired two-tailedStudent t test. Data are repre-
sentative of two independent experiments. Each symbol represents an individual mouse with the line at the mean.
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Supplementary Figure E3. Characterofization of circulating iron, bone marrow erythropoiesis, and erythrocyte half-life of Prkab1-deficient mice. (A)
Plasma ferritin concentration. (B) Plasma iron concentration. (C) Representative H&E stained bone marrow sections from Prkab1þ/þ and Prkab1tm1b/tm1b
mice (400 magnification). (D) Erythroid (Ter119)/Leukocyte (CD45) ratio of bone marrow from Prkab1þ/þ and Prkab1tm1b/tm1b mice. (E) Characterization
of erythropoiesis in the bone marrow of Prkab1þ/þ and Prkab1tm1b/tm1b mice. In vivo half-life of erythrocytes transferred into Prkab1þ/þ (F) or
Prkab1tm1b/tm1b (G) mice. For all, *p! 0.05, ***p! 0.001, and ****p! 0.0001, unpaired two-tailed Student t test, except for Ter119/CD45 ratio, which
was analyzed with a Mann–Whitney test. Data are representative of two independent experiments or four mice for histology analysis. Each symbol represents
an individual mouse with the line at the mean, except for (F) and (G), where n 5 5 with mean 6 standard error of the mean.
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